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REPLY 
Sir, 
Kindly refer to the comments of Duggal 
and Nizamie on our paper. We are grateful to 
them for the interest shown in our paper. Our 
responses to their comments are given below-
I. The commetators have suggested that the 
PANSS should have been administered 
before and after the wash-out period. This has been 
clearly stated in the methodology section that 
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PANSS was done before and after wash-out and 
people showing 20% improvement were dropped. 
2. The concept of primary and secondary 
negative symptoms is still evolving and at the 
time the study was undertaken in 1996 this issue 
has not yet crystalised. That is why no attempt 
was made to differentiate primary from 
secondary negative symptoms. 
3. This study was done on patient consulting 
the clinic, on specified days and fulfilling the 
inclusion and exclusion criteria. Stability of 
symptomatology was not a criteria. However, 
chronic schizophrenic patients who had acute 
exacerbation were excluded. It has been also 
clearly stated in methodology thus the patients 
were more or less stable. 
4. There were 71 patients on 8 mg & 28 
(37%) of them developed EPS whereas, 
75 patients were on 6 mg & 37 (49%) developed 
EPS. Thus the dose of 6 and 8 mg did not show 
much difference on development of EPS in these 
patients. US/Canada study, also showed that 
patients on risperidone need same amount of 
anticholenergics as patients on haloperidol. 
5. Dose escalation was done as per 
recommended protocol at that time. It is possible 
that increase in autonomic instability was due to 
this reason. 
6. Clinical drug trial do recommend flexible 
dose design. In this study fixed dose design was 
used to study the acceptability of two 
recommended dosage. Earlier studies on 
risperidone have also used fixed dose design. 
The conclusions of any study have to 
be interpreted keeping in mind the strength and 
weaknesses of the study. A good study should 
allow readers to make independent conclusions. 
A.K. AGARWAL, MD.DPM.Head, Department of Psychiatry, 
KGs Medical College, Lucknow . 
RISPERIDONE INDUCED DYSTONIC 
REACTION AND AKATHISIA 
Sir, 
P.N. Suresh Kumar has reported acute 
dystonic reaction and akathisia in a patient who 
was given risperidone 3 rng b.i.d. in early part of 
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initiating therapy (Indian Journal of Psychiatry, 
1999, 41,1, 81-82). Acute dystonia is reported 
to have occured in early part of therapy with 
commonly used psychopharmacological agents 
(Kuruvilla & Kuruvilla, 1995) but no case of 
akathisia was observed in a multicenter trial of 
risperidone in Indian patients with schizophrenia 
(Agarwal et al.,1998). Occurence of EPS in 
patients receiving risperidone is said to be dose 
related and it has a reduced propensity to cause 
akathisia (Owens, 1996). Therefore the author's 
observation of acute dystonia and akathisia 
deserves attention and a careful observation for 
EPS in patients receiving risperidone, is required. 
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REPLY 
Sir, 
I am grateful to Dr.S.K.Pandey for his 
interest and valuable comment on the article 
"Risperidone induced dystonia and akathisia". 
Though risperidone is reported to have a broad 
spectrum of antipsychotic activitity it has a 
differential side effect profile at different doses. At 
a dose of 6 mg per day, risperidone demonstrates 
higher 5-HT2 (80-100%) than D2 (74-83%) 
occupancy bordering on the extrapyramidal 
THE EDITOR 
threshold. At this dose the presence of potent 
5-HT2 antagonism may reduce risperidone's risk 
of E.P.S. in comparison with conventional 
antipsychotics. As the dose of risperidone is 
increased beyond 6 mg/day suprathreshold D2 
blockade may result and the balanced serotonin 
dopamine interaction may no longer be able to 
alleviate extrapyramidal symptoms (Kapur & 
Remington, 1996). Marder et al. (1994) in a study 
of assessment of the efficacy of risperidone in the 
treatment of schizophrenia did not find any 
significant difference in extrapyramidal symptom 
rating scale score between patients who received 
placebo and < 6 mg of risperidone. However, in 
the index case report Mr.B was receiving only 6 
mg of risperidone per day still he experienced 
dystonic reaction and intractable akathesia which 
was not relieved by propranolol 120 mg/day. One 
possible reason for the expression of these side 
effects at a "safer therapeutic window" could be 
due to racial changes in the pharmacokinetics and 
pharmacodynamic profile of patients in India 
making them more susceptible to extrapyramidal 
side effects. May be our patients achieving higher 
D2 occupancy at a lower therapeutic dose. In 
contradiction to Dr.S K.Pandey's comment, 14 
(8.5%) cases of akathisia has been reported in the 
multicenter trial of risperidone in Indian patients 
with schizophrenia at the end of 6 weeks therapy 
(Agarwal etal., 1998). In the same series 8 (10.9%) 
patients had rigidity, 29 (17.6%) had hypokinesia 
and 37 (22.4%) had tremor at the end of trial. Out 
of 146 patients 75 received only 6 mg risperidone 
per day. A separate analysis of this two group of 
patients might have given more information about 
the relationship between risperidone's dose and 
extrapyramidal side effects. 
A single case report can only serve to 
stimulate interest in further study. Future studies 
concurrently assessing plasma level, receptor 
occupancy and side effects can answer this 
therapeutic problem. 
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